Bigul

Sanofi India Ltd - 500674 - Postal Ballot - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations').

In terms of Regulation 30 of the SEBI Listing Regulations, we hereby inform that the Board of Directors through resolution by Circulation dated 14th February 2022, approved conducting of Postal Ballot for seeking the approval of members for Material Related Party Transaction(s) with Sanofi Healthcare India Private Limited, Related Party of the Company, by passing an Ordinary Resolution. The Board of Directors have also appointed Mr. Makarand M. Joshi, Partner or failing him Ms. Kumudini Bhalerao, Partner at M/s Makarand M. Joshi & Co., Practicing Company Secretaries, who have given the consent to act as the Scrutinizer, for conducting the Postal Ballot process. The Company shall further intimate the Stock Exchanges on dispatch of the Postal Ballot notice. The Calendar of Events for the proposed postal ballot process is attached for your reference.
15-02-2022
Bigul

Sanofi India Ltd - 500674 - Board Meeting Intimation for Approval Of The Audited Accounts For The Quarter And The Year Ended 31St December 2021 Recommendation Of Final Dividend For The Financial Year Ended 31St December, 2021.

Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/02/2022 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the meeting of the Board of Directors of the Company will be held on Wednesday, 23rd February 2022; inter alia to consider and: approve the audited accounts for the quarter and the year ended 31st December 2021. recommend final dividend for the financial year ended 31st December, 2021. You are requested to take the above on record. Further to our intimation on 27th December 2021, this is to inform you that as per the "Sanofi India Limited- Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons, the trading window of the Company which was closed from January 1, 2022, for publication of financial results of the Company for the quarter and the year ended 31st December, 2021 shall remain closed up to Friday, 25th February, 2022 (inclusive of both days).
07-02-2022
Bigul

Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed.
03-02-2022
Bigul

Sanofi India Ltd - 500674 - Update On Divestment Of Soframycin(r) And Sofradex(r) Businesses - Completion Of The Transaction

Please find enclosed announcement on - Update on Divestment of Soframycin(r) and Sofradex(r) businesses - Completion of the Transaction which is self-explanatory for your information and records.
31-01-2022
Bigul

Sanofi India Ltd - 500674 - Compliance Certificate For The Year Ended 31St December 2021

Pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the compliance certificate for the year ended 31st December 2021.
21-01-2022
Bigul

Sanofi India Ltd - 500674 - Statement Of Investor Complaints For The Quarter Ended December 2021

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- Ms Radhika ShahDesignation :- Company Secretary and Compliance Officer
17-01-2022
Bigul

Sanofi India Ltd - 500674 - Shareholding for the Period Ended December 31, 2021

Sanofi India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here
17-01-2022

Sanofi India MD Rajaram Narayanan resigns

The company's board has accepted the resignation of Rajaram Narayanan, effective from the close of business hours on April 10, 2022, Sanofi India said in a statement.
13-01-2022
Bigul

Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Resignation of Managing Director

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that, Mr. Rajaram Narayanan, Managing Director of the Company has informed the Board of Directors today of his decision to step down as Managing Director, effective close of business hours on April 10, 2022 to pursue an opportunity outside of Sanofi. The Board of Directors have accepted his resignation and place on record their immense appreciation for Mr. Rajaram Narayanan's valuable contribution during his tenure with the Company. The Board will take necessary steps to appoint a suitable successor as the Managing Director of the Company. The Press Release for the above is also attached. Kindly take note of the above in your records.
13-01-2022
Bigul

Sanofi India Ltd - 500674 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Link Intime India Private Limited, Registrar and Share Transfer Agent (RTA) of the Company has provided the enclosed certificate for the quarter ended 31st December 2021 under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Request you to take the above certificate on record.
06-01-2022
Next Page
Close

Let's Open Free Demat Account